Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Treatment Response to Hydroxychloroquine, Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the Pharmacological Outcomes from South Korea

Kim et al., medRxiv, doi:10.1101/2020.05.13.20094193
May 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Hospitalization time 51% Improvement Relative Risk Time to viral- 56% HCQ for COVID-19  Kim et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 97 patients in South Korea Shorter hospitalization (p=0.014) and faster viral clearance (p=0.0047) c19hcq.org Kim et al., medRxiv, May 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020, now with p < 0.00000000001 from 419 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments.
5,200+ studies for 112 treatments. c19hcq.org
Retrospective of 97 moderate cases. Time to viral clearance significantly shorter for HCQ+antibiotic. Preprint withdrawn pending peer review.
hospitalization time, 51.0% lower, relative time 0.49, p = 0.01, treatment 22, control 40.
time to viral-, 56.0% lower, relative time 0.44, p = 0.005, treatment 22, control 40.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kim et al., 18 May 2020, retrospective, South Korea, preprint, 12 authors.
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.05.13.20094193; this version posted June 14, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate COVID-19: A First Report on the Pharmacological Outcomes from South Korea Min Seo Kim, MD, Soon-Woo Jang, MD, KMD, Yu-Kyung Park, MD, Bong-Ok Kim, MD, PhD, Tae-Ho Hwang, DSS, PhD, Seok Ho Kang, MD9, PhD, Won Jun Kim, MD, Park Sung Kyu, MD, Hea-Woon Park, MD, PhD, Wonjong Yang, MD, Joonyoung Jang, MD, Min Ho An, MD The authors have withdrawn this manuscript because of the controversy about hydroxychloroquine and potential changes in results after peer-review, the authors intend to share their results in formal publication. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
{ 'institution': [{'name': 'medRxiv'}], 'indexed': {'date-parts': [[2023, 9, 2]], 'date-time': '2023-09-02T01:30:47Z', 'timestamp': 1693618247422}, 'posted': {'date-parts': [[2020, 5, 18]]}, 'group-title': 'Infectious Diseases (except HIV/AIDS)', 'reference-count': 0, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2020, 6, 14]]}, 'abstract': '<jats:p>The authors have withdrawn this manuscript because of the controversy about ' 'hydroxychloroquine and potential changes in results after peer-review, the authors intend to ' 'share their results in formal publication. Therefore, the authors do not wish this work to be ' 'cited as reference for the project. If you have any questions, please contact the ' 'corresponding author.</jats:p>', 'DOI': '10.1101/2020.05.13.20094193', 'type': 'posted-content', 'created': {'date-parts': [[2020, 5, 18]], 'date-time': '2020-05-18T20:25:13Z', 'timestamp': 1589833513000}, 'source': 'Crossref', 'is-referenced-by-count': 12, 'title': 'Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate ' 'COVID-19: A First Report on the Pharmacological Outcomes from South Korea', 'prefix': '10.1101', 'author': [ {'given': 'Min Seo', 'family': 'Kim', 'sequence': 'first', 'affiliation': []}, {'given': 'Soon-Woo', 'family': 'Jang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yu-Kyung', 'family': 'Park', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bong-Ok', 'family': 'Kim', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tae-Ho', 'family': 'Hwang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Seok Ho', 'family': 'Kang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Won Jun', 'family': 'Kim', 'sequence': 'additional', 'affiliation': []}, {'given': 'Park Sung', 'family': 'Kyu', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hea-Woon', 'family': 'Park', 'sequence': 'additional', 'affiliation': []}, {'given': 'Wonjong', 'family': 'Yang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Joonyoung', 'family': 'Jang', 'sequence': 'additional', 'affiliation': []}, {'given': 'Min Ho', 'family': 'An', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2020.05.13.20094193', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 1, 4]], 'date-time': '2021-01-04T06:50:14Z', 'timestamp': 1609743014000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2020.05.13.20094193'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 5, 18]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.1101/2020.05.13.20094193', 'relation': {}, 'published': {'date-parts': [[2020, 5, 18]]}, 'subtype': 'preprint'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit